{"audit_author": [{"name": "Wyatt, P.G.", "pdbx_ordinal": 1}, {"name": "Woodhead, A.J.", "pdbx_ordinal": 2}, {"name": "Boulstridge, J.A.", "pdbx_ordinal": 3}, {"name": "Berdini, V.", "pdbx_ordinal": 4}, {"name": "Carr, M.G.", "pdbx_ordinal": 5}, {"name": "Cross, D.M.", "pdbx_ordinal": 6}, {"name": "Danillon, D.", "pdbx_ordinal": 7}, {"name": "Davis, D.J.", "pdbx_ordinal": 8}, {"name": "Devine, L.A.", "pdbx_ordinal": 9}, {"name": "Early, T.R.", "pdbx_ordinal": 10}, {"name": "Feltell, R.E.", "pdbx_ordinal": 11}, {"name": "Lewis, E.J.", "pdbx_ordinal": 12}, {"name": "McMenamin, R.L.", "pdbx_ordinal": 13}, {"name": "Navarro, E.F.", "pdbx_ordinal": 14}, {"name": "O'Brien, M.A.", "pdbx_ordinal": 15}, {"name": "O'Reilly, M.", "pdbx_ordinal": 16}, {"name": "Reule, M.", "pdbx_ordinal": 17}, {"name": "Saxty, G.", "pdbx_ordinal": 18}, {"name": "Seavers, L.C.A.", "pdbx_ordinal": 19}, {"name": "Smith, D.", "pdbx_ordinal": 20}, {"name": "Squires, M.S.", "pdbx_ordinal": 21}, {"name": "Trewartha, G.", "pdbx_ordinal": 22}, {"name": "Walker, M.T.", "pdbx_ordinal": 23}, {"name": "Woolford, A.J.", "pdbx_ordinal": 24}], "cell": {"angle_alpha": 90.0, "angle_beta": 90.0, "angle_gamma": 90.0, "length_a": 53.567, "length_b": 71.476, "length_c": 72.116, "zpdb": 4}, "citation": [{"country": "US", "id": "primary", "journal_abbrev": "J.Med.Chem.", "journal_id_astm": "JMCMAR", "journal_id_csd": "0151", "journal_id_issn": "0022-2623", "journal_volume": "51", "page_first": "4986", "page_last": "4999", "pdbx_database_id_doi": "10.1021/JM800382H", "pdbx_database_id_pub_med": 18656911, "rcsb_authors": ["Wyatt, P.G.", "Woodhead, A.J.", "Berdini, V.", "Boulstridge, J.A.", "Carr, M.G.", "Cross, D.M.", "Davis, D.J.", "Devine, L.A.", "Early, T.R.", "Feltell, R.E.", "Lewis, E.J.", "McMenamin, R.L.", "Navarro, E.F.", "O'Brien, M.A.", "O'Reilly, M.", "Reule, M.", "Saxty, G.", "Seavers, L.C.A.", "Smith, D.", "Squires, M.S.", "Trewartha, G.", "Walker, M.T.", "Woolford, A.J."], "rcsb_is_primary": "Y", "rcsb_journal_abbrev": "J Med Chem", "title": "Identification of N-(4-Piperidinyl)-4-(2,6-Dichlorobenzoylamino)-1H-Pyrazole-3-Carboxamide (at7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.", "year": 2008}], "diffrn": [{"ambient_temp": 100.0, "crystal_id": "1", "id": "1"}], "diffrn_detector": [{"details": "OSMIC CONFOCAL BLUE", "detector": "CCD", "diffrn_id": "1", "type": "RIGAKU CCD"}], "diffrn_radiation": [{"diffrn_id": "1", "pdbx_diffrn_protocol": "SINGLE WAVELENGTH", "pdbx_monochromatic_or_laue_ml": "M", "pdbx_scattering_type": "x-ray", "wavelength_id": "1"}], "diffrn_source": [{"diffrn_id": "1", "pdbx_wavelength": "1.5418", "source": "ROTATING ANODE", "type": "RIGAKU RU200HR"}], "entry": {"id": "2VTT"}, "exptl": [{"crystals_number": 1, "method": "X-RAY DIFFRACTION"}], "exptl_crystal": [{"density_matthews": 2.02, "density_percent_sol": 38.7, "description": "NONE", "id": "1"}], "exptl_crystal_grow": [{"crystal_id": "1", "p_h": 6.7, "pdbx_details": "0.1M HEPES/NAOH, PH7.0, 0.0475M AMMONIUM ACETATE, 12% W/V PEG 3350, pH 6.7"}], "pdbx_audit_revision_category": [{"category": "citation", "data_content_type": "Structure model", "ordinal": 1, "revision_ordinal": 4}, {"category": "citation_author", "data_content_type": "Structure model", "ordinal": 2, "revision_ordinal": 4}], "pdbx_audit_revision_details": [{"data_content_type": "Structure model", "ordinal": 1, "provider": "repository", "revision_ordinal": 1, "type": "Initial release"}], "pdbx_audit_revision_group": [{"data_content_type": "Structure model", "group": "Version format compliance", "ordinal": 1, "revision_ordinal": 2}, {"data_content_type": "Structure model", "group": "Version format compliance", "ordinal": 2, "revision_ordinal": 3}, {"data_content_type": "Structure model", "group": "Data collection", "ordinal": 3, "revision_ordinal": 4}, {"data_content_type": "Structure model", "group": "Database references", "ordinal": 4, "revision_ordinal": 4}], "pdbx_audit_revision_history": [{"data_content_type": "Structure model", "major_revision": 1, "minor_revision": 0, "ordinal": 1, "revision_date": "2008-08-05T00:00:00+0000"}, {"data_content_type": "Structure model", "major_revision": 1, "minor_revision": 1, "ordinal": 2, "revision_date": "2011-05-08T00:00:00+0000"}, {"data_content_type": "Structure model", "major_revision": 1, "minor_revision": 2, "ordinal": 3, "revision_date": "2011-07-13T00:00:00+0000"}, {"data_content_type": "Structure model", "major_revision": 1, "minor_revision": 3, "ordinal": 4, "revision_date": "2018-06-20T00:00:00+0000"}], "pdbx_audit_revision_item": [{"data_content_type": "Structure model", "item": "_citation.page_last", "ordinal": 1, "revision_ordinal": 4}, {"data_content_type": "Structure model", "item": "_citation_author.name", "ordinal": 2, "revision_ordinal": 4}], "pdbx_database_related": [{"content_type": "unspecified", "db_id": "1PYE", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR"}, {"content_type": "unspecified", "db_id": "1H08", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR"}, {"content_type": "unspecified", "db_id": "2B53", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325"}, {"content_type": "unspecified", "db_id": "1V1K", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR"}, {"content_type": "unspecified", "db_id": "1OKV", "db_name": "PDB", "details": "CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2"}, {"content_type": "unspecified", "db_id": "1KE7", "db_name": "PDB", "details": "CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE"}, {"content_type": "unspecified", "db_id": "1H25", "db_name": "PDB", "details": "CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F"}, {"content_type": "unspecified", "db_id": "1PXK", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE"}, {"content_type": "unspecified", "db_id": "2BHH", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE"}, {"content_type": "unspecified", "db_id": "2VTA", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2UUE", "db_name": "PDB", "details": "REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS"}, {"content_type": "unspecified", "db_id": "1E1V", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058"}, {"content_type": "unspecified", "db_id": "1GZ8", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE"}, {"content_type": "unspecified", "db_id": "1OL2", "db_name": "PDB", "details": "CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2"}, {"content_type": "unspecified", "db_id": "1H27", "db_name": "PDB", "details": "CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27"}, {"content_type": "unspecified", "db_id": "1JSV", "db_name": "PDB", "details": "THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE"}, {"content_type": "unspecified", "db_id": "2B52", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562"}, {"content_type": "unspecified", "db_id": "1KE5", "db_name": "PDB", "details": "CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE"}, {"content_type": "unspecified", "db_id": "1FIN", "db_name": "PDB", "details": "CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX"}, {"content_type": "unspecified", "db_id": "2C5O", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "2C68", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1P2A", "db_name": "PDB", "details": "THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR"}, {"content_type": "unspecified", "db_id": "2C4G", "db_name": "PDB", "details": "STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514"}, {"content_type": "unspecified", "db_id": "1W0X", "db_name": "PDB", "details": "CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE."}, {"content_type": "unspecified", "db_id": "1H1Q", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094"}, {"content_type": "unspecified", "db_id": "1PXO", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-AMINE"}, {"content_type": "unspecified", "db_id": "1KE9", "db_name": "PDB", "details": "CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE"}, {"content_type": "unspecified", "db_id": "2A0C", "db_name": "PDB", "details": "HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1HCK", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2"}, {"content_type": "unspecified", "db_id": "1JSU", "db_name": "PDB", "details": "P27(KIP1)/CYCLIN A/CDK2 COMPLEX"}, {"content_type": "unspecified", "db_id": "1PXN", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL"}, {"content_type": "unspecified", "db_id": "2UZE", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2V0D", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1OIQ", "db_name": "PDB", "details": "IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION"}, {"content_type": "unspecified", "db_id": "1H1R", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086"}, {"content_type": "unspecified", "db_id": "2IW8", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1HCL", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2"}, {"content_type": "unspecified", "db_id": "1GIH", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR"}, {"content_type": "unspecified", "db_id": "1PW2", "db_name": "PDB", "details": "APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2"}, {"content_type": "unspecified", "db_id": "1JST", "db_name": "PDB", "details": "PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A"}, {"content_type": "unspecified", "db_id": "1OIU", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1PXM", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL"}, {"content_type": "unspecified", "db_id": "1B38", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2"}, {"content_type": "unspecified", "db_id": "1FQ1", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2"}, {"content_type": "unspecified", "db_id": "1VYW", "db_name": "PDB", "details": "STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137"}, {"content_type": "unspecified", "db_id": "1H1P", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058"}, {"content_type": "unspecified", "db_id": "2C69", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1URC", "db_name": "PDB", "details": "CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2"}, {"content_type": "unspecified", "db_id": "1PXI", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE"}, {"content_type": "unspecified", "db_id": "2C6I", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1YKR", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR"}, {"content_type": "unspecified", "db_id": "2C6K", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2UZD", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2C5Y", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "1WCC", "db_name": "PDB", "details": "SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY"}, {"content_type": "unspecified", "db_id": "2J9M", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE"}, {"content_type": "unspecified", "db_id": "1VYZ", "db_name": "PDB", "details": "STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227"}, {"content_type": "unspecified", "db_id": "1JVP", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365"}, {"content_type": "unspecified", "db_id": "1W98", "db_name": "PDB", "details": "THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E"}, {"content_type": "unspecified", "db_id": "1PKD", "db_name": "PDB", "details": "THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A"}, {"content_type": "unspecified", "db_id": "1P5E", "db_name": "PDB", "details": "THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS)"}, {"content_type": "unspecified", "db_id": "2C5P", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "2UZN", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2B54", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305"}, {"content_type": "unspecified", "db_id": "1KE6", "db_name": "PDB", "details": "CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE"}, {"content_type": "unspecified", "db_id": "1PXJ", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE"}, {"content_type": "unspecified", "db_id": "2UZL", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2CCI", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6"}, {"content_type": "unspecified", "db_id": "2BKZ", "db_name": "PDB", "details": "STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611"}, {"content_type": "unspecified", "db_id": "2G9X", "db_name": "PDB", "details": "STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271"}, {"content_type": "unspecified", "db_id": "1Y91", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2IW6", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1GIJ", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR"}, {"content_type": "unspecified", "db_id": "1R78", "db_name": "PDB", "details": "CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1H0V", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE"}, {"content_type": "unspecified", "db_id": "2IW9", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1W8C", "db_name": "PDB", "details": "CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2"}, {"content_type": "unspecified", "db_id": "1BUH", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1"}, {"content_type": "unspecified", "db_id": "2BPM", "db_name": "PDB", "details": "STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529"}, {"content_type": "unspecified", "db_id": "2BTS", "db_name": "PDB", "details": "STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032"}, {"content_type": "unspecified", "db_id": "1FVV", "db_name": "PDB", "details": "THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR"}, {"content_type": "unspecified", "db_id": "1OKW", "db_name": "PDB", "details": "CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2"}, {"content_type": "unspecified", "db_id": "2A4L", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE"}, {"content_type": "unspecified", "db_id": "2C6T", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1FVT", "db_name": "PDB", "details": "THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1QMZ", "db_name": "PDB", "details": "PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX"}, {"content_type": "unspecified", "db_id": "1OGU", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2B55", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE DIN-101312"}, {"content_type": "unspecified", "db_id": "1PF8", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1H1S", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102"}, {"content_type": "unspecified", "db_id": "2C5V", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "2JGZ", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B"}, {"content_type": "unspecified", "db_id": "2BHE", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO- INDIRUBINE"}, {"content_type": "unspecified", "db_id": "1URW", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE"}, {"content_type": "unspecified", "db_id": "1OIY", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2C6L", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1F5Q", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2"}, {"content_type": "unspecified", "db_id": "2C6O", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1OL1", "db_name": "PDB", "details": "CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2"}, {"content_type": "unspecified", "db_id": "2UZB", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1H01", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR"}, {"content_type": "unspecified", "db_id": "1OIR", "db_name": "PDB", "details": "IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION"}, {"content_type": "unspecified", "db_id": "1OI9", "db_name": "PDB", "details": "STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2CJM", "db_name": "PDB", "details": "MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE"}, {"content_type": "unspecified", "db_id": "2C5N", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "2C5X", "db_name": "PDB", "details": "DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN"}, {"content_type": "unspecified", "db_id": "2C6M", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1OIT", "db_name": "PDB", "details": "IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION"}, {"content_type": "unspecified", "db_id": "2V22", "db_name": "PDB", "details": "REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS"}, {"content_type": "unspecified", "db_id": "1GY3", "db_name": "PDB", "details": "PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE"}, {"content_type": "unspecified", "db_id": "1GII", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR"}, {"content_type": "unspecified", "db_id": "1DI8", "db_name": "PDB", "details": "THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE"}, {"content_type": "unspecified", "db_id": "1E9H", "db_name": "PDB", "details": "THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND"}, {"content_type": "unspecified", "db_id": "1DM2", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE"}, {"content_type": "unspecified", "db_id": "2UZO", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR"}, {"content_type": "unspecified", "db_id": "1H24", "db_name": "PDB", "details": "CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F"}, {"content_type": "unspecified", "db_id": "1H00", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR"}, {"content_type": "unspecified", "db_id": "2EXM", "db_name": "PDB", "details": "HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE"}, {"content_type": "unspecified", "db_id": "2CLX", "db_name": "PDB", "details": "4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS"}, {"content_type": "unspecified", "db_id": "1PXP", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,4-DIAMINE"}, {"content_type": "unspecified", "db_id": "2CCH", "db_name": "PDB", "details": "THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE"}, {"content_type": "unspecified", "db_id": "1B39", "db_name": "PDB", "details": "HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160"}, {"content_type": "unspecified", "db_id": "2BTR", "db_name": "PDB", "details": "STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873"}, {"content_type": "unspecified", "db_id": "1AQ1", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE"}, {"content_type": "unspecified", "db_id": "1H0W", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE"}, {"content_type": "unspecified", "db_id": "1G5S", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717"}, {"content_type": "unspecified", "db_id": "1CKP", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B"}, {"content_type": "unspecified", "db_id": "1PXL", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-AMINE"}, {"content_type": "unspecified", "db_id": "1KE8", "db_name": "PDB", "details": "CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE"}, {"content_type": "unspecified", "db_id": "1H28", "db_name": "PDB", "details": "CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107"}, {"content_type": "unspecified", "db_id": "1H26", "db_name": "PDB", "details": "CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53"}, {"content_type": "unspecified", "db_id": "1H07", "db_name": "PDB", "details": "CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR"}, {"content_type": "unspecified", "db_id": "1E1X", "db_name": "PDB", "details": "HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027"}, {"content_type": "unspecified", "db_id": "1Y8Y", "db_name": "PDB", "details": "CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR"}, {"content_type": "unspecified", "db_id": "2VTH", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTI", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTJ", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTL", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTM", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTN", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTO", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTP", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTQ", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTR", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}, {"content_type": "unspecified", "db_id": "2VTS", "db_name": "PDB", "details": "IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN."}], "pdbx_database_status": {"deposit_site": "PDBE", "pdb_format_compatible": "Y", "process_site": "PDBE", "recvd_initial_deposition_date": "2008-05-15T00:00:00+0000", "status_code": "REL"}, "pdbx_vrpt_summary": {"babinet_b": 58.531, "babinet_k": 0.395, "dcc_r": 0.2, "eds_r": 0.2, "fo_fc_correlation": 0.951, "pdb_r": 0.2, "wilson_baniso": "[24.445,27.705,21.164,0.000,0.000,0.000]", "wilson_bestimate": 24.195, "absolute_percentile_dccrfree": 47.0, "absolute_percentile_clashscore": 15.2, "absolute_percentile_percent_rsrzoutliers": 6.2, "absolute_percentile_percent_ramachandran_outliers": 34.0, "absolute_percentile_percent_rotamer_outliers": 33.7, "acentric_outliers": 1, "angles_rmsz": 0.69, "attempted_validation_steps": "molprobity,validation-pack,xtriage,eds,mogul,buster-report,percentiles,writexml", "bonds_rmsz": 0.61, "bulk_solvent_b": 56.603, "bulk_solvent_k": 0.357, "ccp4version": "7.0.044 (Gargrove)", "centric_outliers": 0.0, "clashscore": 14.93, "data_anisotropy": 0.268, "data_completeness": 76.33, "high_resol_relative_percentile_dccrfree": 1.66, "high_resol_relative_percentile_clashscore": 1.66, "high_resol_relative_percentile_percent_rsrzoutliers": 1.66, "high_resol_relative_percentile_percent_ramachandran_outliers": 1.66, "high_resol_relative_percentile_percent_rotamer_outliers": 1.66, "low_resol_relative_percentile_dccrfree": 1.7, "low_resol_relative_percentile_clashscore": 1.7, "low_resol_relative_percentile_percent_rsrzoutliers": 1.7, "low_resol_relative_percentile_percent_ramachandran_outliers": 1.7, "low_resol_relative_percentile_percent_rotamer_outliers": 1.7, "no_ligands_for_buster_report": "yes", "num_hreduce": 2269.0, "num_pdbids_absolute_percentile_dccrfree": 130704, "num_pdbids_absolute_percentile_clashscore": 141614, "num_pdbids_absolute_percentile_percent_rsrzoutliers": 127900, "num_pdbids_absolute_percentile_percent_ramachandran_outliers": 138981, "num_pdbids_absolute_percentile_percent_rotamer_outliers": 138945, "num_pdbids_relative_percentile_dccrfree": 6780, "num_pdbids_relative_percentile_clashscore": 7310, "num_pdbids_relative_percentile_percent_rsrzoutliers": 6661, "num_pdbids_relative_percentile_percent_ramachandran_outliers": 7173, "num_pdbids_relative_percentile_percent_rotamer_outliers": 7172, "num_angles_rmsz": 3047, "num_bonds_rmsz": 2250, "num_free_reflections": 1220, "num_miller_indices": 24602, "percent_rsrzoutliers": 10.29, "percent_free_reflections": 4.96, "percent_ramachandran_outliers": 0.38, "percent_rotamer_outliers": 3.73, "percentilebins": ["all", "1.68", "xray"], "protein_dnarnaentities": "1", "refmac_version": "5.8.0158", "relative_percentile_dccrfree": 19.0, "relative_percentile_clashscore": 4.1, "relative_percentile_percent_rsrzoutliers": 6.5, "relative_percentile_percent_ramachandran_outliers": 17.1, "relative_percentile_percent_rotamer_outliers": 13.2, "report_creation_date": "May 13, 2020 -- 11:49 am BST", "restypes_notchecked_for_bond_angle_geometry": ["LZD"], "trans_nsc": "The largest off-origin peak in the Patterson function is 5.59% of the height of the origin peak. No significant pseudotranslation is detected.", "twin_l": 0.486, "twin_l2": 0.315, "twin_fraction": "-h,l,k:0.000", "xtriage_input_columns": "F_meas_au,F_meas_sigma_au", "bfactor_type": "FULL", "dccrfree": 0.24, "dccrefinement_program": "REFMAC", "edsresolution": 1.68, "edsresolution_low": 43.0, "iover_sigma": "2.48(1.68A)", "pdbrfree": 0.23, "pdbdeposition_date": "2008-05-15T00:00:00+0000", "pdbresolution": 1.68, "pdbresolution_low": 43.0, "pdbrevision_date": "2018-06-20T00:00:00+0000", "pdbrevision_number": 4.0}, "rcsb_accession_info": {"deposit_date": "2008-05-15T00:00:00+0000", "has_released_experimental_data": "N", "initial_release_date": "2008-08-05T00:00:00+0000", "major_revision": 1, "minor_revision": 3, "revision_date": "2018-06-20T00:00:00+0000", "status_code": "REL"}, "rcsb_entry_container_identifiers": {"assembly_ids": ["1"], "entity_ids": ["1", "2", "3"], "entry_id": "2VTT", "model_ids": [1], "non_polymer_entity_ids": ["2"], "polymer_entity_ids": ["1"], "rcsb_id": "2VTT", "pubmed_id": 18656911}, "rcsb_entry_info": {"assembly_count": 1, "branched_entity_count": 0, "cis_peptide_count": 1, "deposited_atom_count": 2438, "deposited_hydrogen_atom_count": 0, "deposited_model_count": 1, "deposited_modeled_polymer_monomer_count": 272, "deposited_nonpolymer_entity_instance_count": 1, "deposited_polymer_entity_instance_count": 1, "deposited_polymer_monomer_count": 298, "deposited_solvent_atom_count": 218, "deposited_unmodeled_polymer_monomer_count": 26, "diffrn_radiation_wavelength_maximum": 1.5418, "diffrn_radiation_wavelength_minimum": 1.5418, "disulfide_bond_count": 0, "entity_count": 3, "experimental_method": "X-ray", "experimental_method_count": 1, "inter_mol_covalent_bond_count": 0, "inter_mol_metalic_bond_count": 0, "molecular_weight": 34.33, "na_polymer_entity_types": "Other", "nonpolymer_entity_count": 1, "nonpolymer_molecular_weight_maximum": 0.35, "nonpolymer_molecular_weight_minimum": 0.35, "polymer_composition": "homomeric protein", "polymer_entity_count": 1, "polymer_entity_count_dna": 0, "polymer_entity_count_rna": 0, "polymer_entity_count_nucleic_acid": 0, "polymer_entity_count_nucleic_acid_hybrid": 0, "polymer_entity_count_protein": 1, "polymer_entity_taxonomy_count": 1, "polymer_molecular_weight_maximum": 33.98, "polymer_molecular_weight_minimum": 33.98, "polymer_monomer_count_maximum": 298, "polymer_monomer_count_minimum": 298, "resolution_combined": [1.68], "selected_polymer_entity_types": "Protein (only)", "software_programs_combined": ["AMORE", "BUSTER-TNT", "CRYSTALCLEAR"], "solvent_entity_count": 1, "structure_determination_methodology": "experimental", "structure_determination_methodology_priority": 10, "diffrn_resolution_high": {"provenance_source": "Depositor assigned", "value": 1.68}}, "rcsb_primary_citation": {"country": "US", "id": "primary", "journal_abbrev": "J.Med.Chem.", "journal_id_astm": "JMCMAR", "journal_id_csd": "0151", "journal_id_issn": "0022-2623", "journal_volume": "51", "page_first": "4986", "page_last": "4999", "pdbx_database_id_doi": "10.1021/JM800382H", "pdbx_database_id_pub_med": 18656911, "rcsb_authors": ["Wyatt, P.G.", "Woodhead, A.J.", "Berdini, V.", "Boulstridge, J.A.", "Carr, M.G.", "Cross, D.M.", "Davis, D.J.", "Devine, L.A.", "Early, T.R.", "Feltell, R.E.", "Lewis, E.J.", "McMenamin, R.L.", "Navarro, E.F.", "O'Brien, M.A.", "O'Reilly, M.", "Reule, M.", "Saxty, G.", "Seavers, L.C.A.", "Smith, D.", "Squires, M.S.", "Trewartha, G.", "Walker, M.T.", "Woolford, A.J."], "rcsb_journal_abbrev": "J Med Chem", "title": "Identification of N-(4-Piperidinyl)-4-(2,6-Dichlorobenzoylamino)-1H-Pyrazole-3-Carboxamide (at7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.", "year": 2008}, "refine": [{"aniso_b11": 0.78748772, "aniso_b12": 0.0, "aniso_b13": 0.0, "aniso_b22": -3.48393787, "aniso_b23": 0.0, "aniso_b33": 2.69645014, "ls_rfactor_rfree": 0.2274, "ls_rfactor_rwork": 0.1994, "ls_rfactor_obs": 0.2008, "ls_dres_high": 1.68, "ls_dres_low": 43.0, "ls_number_reflns_rfree": 1220, "ls_number_reflns_obs": 24602, "ls_percent_reflns_rfree": 4.96, "ls_percent_reflns_obs": 76.19, "pdbx_rfree_selection_details": "RANDOM", "pdbx_diffrn_id": ["1"], "pdbx_ls_cross_valid_method": "THROUGHOUT", "pdbx_ls_sigma_f": 0.0, "pdbx_method_to_determine_struct": "MOLECULAR REPLACEMENT", "pdbx_refine_id": "X-RAY DIFFRACTION", "pdbx_starting_model": "IN-HOUSE STRUCTURE", "biso_mean": 33.88}], "refine_hist": [{"cycle_id": "LAST", "d_res_high": 1.68, "d_res_low": 43.0, "number_atoms_solvent": 218, "number_atoms_total": 2438, "pdbx_number_atoms_ligand": 25, "pdbx_number_atoms_nucleic_acid": 0, "pdbx_number_atoms_protein": 2195, "pdbx_refine_id": "X-RAY DIFFRACTION"}], "reflns": [{"d_resolution_high": 1.68, "d_resolution_low": 43.0, "number_obs": 24602, "observed_criterion_sigma_i": 0.0, "pdbx_rmerge_iobs": 0.03, "pdbx_diffrn_id": ["1"], "pdbx_net_iover_sigma_i": 26.68, "pdbx_ordinal": 1, "pdbx_redundancy": 3.1, "percent_possible_obs": 76.2, "biso_wilson_estimate": 26.931}], "reflns_shell": [{"rmerge_iobs": 0.24, "d_res_high": 1.68, "d_res_low": 1.74, "mean_iover_sig_iobs": 1.6, "pdbx_diffrn_id": ["1"], "pdbx_ordinal": 1, "percent_possible_all": 12.8}], "software": [{"classification": "refinement", "name": "BUSTER-TNT", "pdbx_ordinal": 1, "version": "2.1.1"}, {"classification": "data reduction", "name": "CrystalClear", "pdbx_ordinal": 2}, {"classification": "data scaling", "name": "CrystalClear", "pdbx_ordinal": 3}, {"classification": "phasing", "name": "AMoRE", "pdbx_ordinal": 4}], "struct": {"pdbx_descriptor": "CELL DIVISION PROTEIN KINASE 2 (E.C.2.7.11.1, 2.7.11.22)", "title": "Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design."}, "struct_keywords": {"pdbx_keywords": "TRANSFERASE", "text": "TRANSFERASE, MITOSIS, CELL CYCLE, SERINE/THREONINE PROTEIN KINASE"}, "symmetry": {"int_tables_number": 19, "space_group_name_hm": "P 21 21 21"}, "rcsb_id": "2VTT", "rcsb_binding_affinity": [{"comp_id": "LZD", "type": "IC50", "value": 44.0, "unit": "nM", "reference_sequence_identity": 100, "provenance_code": "BindingDB", "link": "http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_pdbids.jsp?pdbids_submit=Search&pdbids=2VTT"}, {"comp_id": "LZD", "type": "IC50", "value": 44.0, "unit": "nM", "provenance_code": "PDBBind", "link": "http://www.pdbbind-cn.org/quickpdb.php?quickpdb=2vtt"}, {"comp_id": "LZD", "type": "IC50", "value": 44.0, "unit": "nM", "provenance_code": "Binding MOAD", "link": "http://www.bindingmoad.org/pdbrecords/index/2vtt"}]}